Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a pharmaceutical company based in Rockville, Maryland, founded in 2005. The company specializes in developing and commercializing products for central nervous system (CNS) diseases. Supernus focuses on conditions such as epilepsy, migraine, attention deficit hyperactivity disorder (ADHD), and rare diseases. The company offers several FDA-approved medications, including Oxtellar XR for epilepsy, Trokendi XR for epilepsy and migraine prevention, Qelbree for pediatric and adult ADHD, and Sumavel DosePro for rare diseases. Supernus has expanded its capabilities through strategic acquisitions, including Biotie Therapies Corp. in 2024. Under the leadership of President and CEO Jack Khattar, Supernus Pharmaceuticals is dedicated to addressing unmet medical needs in neurology and psychiatry, serving healthcare providers, neurologists, psychiatrists, and patients.
Work at Supernus Pharmaceuticals in HR or recruiting? Claim this page
Headcount trend
Supernus Pharmaceuticals went from 637 employees in Jul 2023 to 686 in Jun 2025. Jan to Jun 2025: 28 people joined, 14 left.
Headcount data through Jun 2025
Org structure
Headcount by department
Executive compensation
Hiring now
See all jobsSalaries at Supernus Pharmaceuticals
All salaries1 salary profiles in the US
Peer reviews
Worked with someone at Supernus Pharmaceuticals?
Anonymous peer reviews on OffTheRecord
Similar companies
Supernus Pharmaceuticals FAQ
How many employees does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has about 686 employees, up 2.2% over the 3 months to Jun 2025.
What is Supernus Pharmaceuticals's revenue per employee?
Supernus Pharmaceuticals makes about $974K in revenue per employee, based on $668M annual revenue and 686 employees.
How much does Supernus Pharmaceuticals pay?
6figr has 1 salary profile for Supernus Pharmaceuticals in the US, with pay broken down by role, level, gender and ethnicity on the Supernus Pharmaceuticals salaries page. See Supernus Pharmaceuticals salaries
Is Supernus Pharmaceuticals a public company?
Yes. Supernus Pharmaceuticals is publicly traded under the ticker SUPN on NASDAQ.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.